Aytu BioPharma (AYTU) Competitors $2.19 -0.10 (-4.37%) Closing price 08/14/2025 04:00 PM EasternExtended Trading$2.20 +0.01 (+0.46%) As of 08/14/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AYTU vs. AVTX, VXRT, EXOZ, MGX, ELUT, BYSI, EPIX, ANRO, WHWK, and ABOSShould you be buying Aytu BioPharma stock or one of its competitors? The main competitors of Aytu BioPharma include Avalo Therapeutics (AVTX), Vaxart (VXRT), eXoZymes (EXOZ), Metagenomi (MGX), Elutia (ELUT), BeyondSpring (BYSI), ESSA Pharma (EPIX), Alto Neuroscience (ANRO), Whitehawk Therapeutics (WHWK), and Acumen Pharmaceuticals (ABOS). These companies are all part of the "pharmaceutical products" industry. Aytu BioPharma vs. Its Competitors Avalo Therapeutics Vaxart eXoZymes Metagenomi Elutia BeyondSpring ESSA Pharma Alto Neuroscience Whitehawk Therapeutics Acumen Pharmaceuticals Avalo Therapeutics (NASDAQ:AVTX) and Aytu BioPharma (NASDAQ:AYTU) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment. Do analysts rate AVTX or AYTU? Avalo Therapeutics presently has a consensus target price of $30.00, indicating a potential upside of 235.20%. Aytu BioPharma has a consensus target price of $10.00, indicating a potential upside of 356.62%. Given Aytu BioPharma's higher probable upside, analysts clearly believe Aytu BioPharma is more favorable than Avalo Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avalo Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Aytu BioPharma 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable earnings and valuation, AVTX or AYTU? Aytu BioPharma has higher revenue and earnings than Avalo Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvalo Therapeutics$440K267.48-$35.13MN/AN/AAytu BioPharma$81M0.24-$15.84M-$0.72-3.04 Is AVTX or AYTU more profitable? Aytu BioPharma has a net margin of 2.37% compared to Avalo Therapeutics' net margin of 0.00%. Aytu BioPharma's return on equity of 3.51% beat Avalo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Avalo TherapeuticsN/A -48.48% -35.94% Aytu BioPharma 2.37%3.51%0.91% Which has more volatility & risk, AVTX or AYTU? Avalo Therapeutics has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500. Comparatively, Aytu BioPharma has a beta of 0.13, meaning that its share price is 87% less volatile than the S&P 500. Do institutionals & insiders believe in AVTX or AYTU? 87.1% of Avalo Therapeutics shares are held by institutional investors. Comparatively, 33.5% of Aytu BioPharma shares are held by institutional investors. 3.0% of Avalo Therapeutics shares are held by insiders. Comparatively, 3.6% of Aytu BioPharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media refer more to AVTX or AYTU? In the previous week, Avalo Therapeutics had 4 more articles in the media than Aytu BioPharma. MarketBeat recorded 5 mentions for Avalo Therapeutics and 1 mentions for Aytu BioPharma. Aytu BioPharma's average media sentiment score of 1.87 beat Avalo Therapeutics' score of 0.08 indicating that Aytu BioPharma is being referred to more favorably in the news media. Company Overall Sentiment Avalo Therapeutics Neutral Aytu BioPharma Very Positive SummaryAytu BioPharma beats Avalo Therapeutics on 8 of the 13 factors compared between the two stocks. Get Aytu BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for AYTU and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AYTU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AYTU vs. The Competition Export to ExcelMetricAytu BioPharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$20.56M$3.10B$5.62B$9.84BDividend YieldN/A2.23%4.61%4.07%P/E Ratio-3.0420.4930.2925.74Price / Sales0.24356.37463.41115.83Price / CashN/A43.0338.2159.48Price / Book0.478.608.826.15Net Income-$15.84M-$54.65M$3.25B$265.06M7 Day Performance-7.59%5.86%3.71%2.60%1 Month Performance0.92%8.86%5.85%2.83%1 Year Performance-15.64%13.33%29.92%25.58% Aytu BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AYTUAytu BioPharma3.7876 of 5 stars$2.19-4.4%$10.00+356.6%-12.4%$20.56M$81M-3.04160News CoveragePositive NewsGap DownAVTXAvalo Therapeutics3.2371 of 5 stars$8.97+13.7%$30.00+234.4%-6.6%$85.43M$440K0.0040Short Interest ↓VXRTVaxart3.051 of 5 stars$0.37+4.0%$3.00+711.0%-39.1%$84.68M$47.40M-1.37120News CoverageGap DownEXOZeXoZymesN/A$9.94-1.3%N/AN/A$84.31M$70K0.0029News CoverageEarnings ReportGap DownMGXMetagenomi2.5937 of 5 stars$2.30+2.2%$13.00+465.2%-38.7%$84.11M$52.29M-1.09236News CoverageEarnings ReportAnalyst ForecastELUTElutia3.9489 of 5 stars$1.99-2.5%$8.00+302.0%-34.8%$83.88M$24.38M-1.03180News CoverageEarnings ReportBYSIBeyondSpringN/A$2.16+4.3%N/A+10.4%$83.46M$1.75M0.0080News CoverageEarnings ReportEPIXESSA Pharma1.4287 of 5 stars$1.88flat$2.00+6.4%-57.6%$83.45MN/A-2.9850News CoverageEarnings ReportANROAlto Neuroscience1.9047 of 5 stars$3.07+0.7%$8.50+176.9%-67.2%$82.57MN/A-1.31N/ATrending NewsEarnings ReportWHWKWhitehawk TherapeuticsN/A$1.76+1.1%N/AN/A$81.97M$27.78M11.0040ABOSAcumen Pharmaceuticals3.2446 of 5 stars$1.33-1.5%$6.33+376.2%-44.3%$81.77MN/A-0.6920Earnings Report Related Companies and Tools Related Companies Avalo Therapeutics Alternatives Vaxart Alternatives eXoZymes Alternatives Metagenomi Alternatives Elutia Alternatives BeyondSpring Alternatives ESSA Pharma Alternatives Alto Neuroscience Alternatives Whitehawk Therapeutics Alternatives Acumen Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AYTU) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aytu BioPharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aytu BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access